COEP (Coeptis Therapeutics Holdings) 3-Year EBITDA Growth Rate: 63.60% (As of Dec. 2025) — 136% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COEP Coeptis Therapeutics Holdings Inc COEP
12 GF Score
Price $16.40
View Full Analysis

What is Coeptis Therapeutics Holdings 3-Year EBITDA Growth Rate?

Coeptis Therapeutics Holdings COEP +1.52% 12 3-Year EBITDA Growth Rate is 63.60% as of Dec. 2025, which is 136% above its 10-year median of 27.00. GuruFocus rates COEP with a GF Score™ of 12/100.

Coeptis Therapeutics Holdings's EBITDA per Share for the three months ended in Dec. 2025 was $-0.16.

During the past 3 years, the average EBITDA Per Share Growth Rate was 63.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 25.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Coeptis Therapeutics Holdings was 63.60% per year. The lowest was -22.60% per year. And the median was 27.00% per year.

Coeptis Therapeutics Holdings  (NAS:COEP) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Coeptis Therapeutics Holdings 3-Year EBITDA Growth Rate Related Terms

COEP vs ANIX, COYA, PMN: 3-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Coeptis Therapeutics Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coeptis Therapeutics Holdings 3-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coeptis Therapeutics Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Coeptis Therapeutics Holdings's 3-Year EBITDA Growth Rate falls into.


COEP
12GF Score
Coeptis Therapeutics Holdings Inc COEP
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coeptis Therapeutics Holdings 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 63.60% mean?
Coeptis Therapeutics Holdings (COEP) has a 3-Year EBITDA Growth Rate of 63.60% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Coeptis Therapeutics Holdings and its competitors. This is 136% above median its historical median of 27.00.
Is Coeptis Therapeutics Holdings' 3-Year EBITDA Growth Rate too high?
Coeptis Therapeutics Holdings' current 3-Year EBITDA Growth Rate of 63.60% is 136% above median its 10-year median of 27.00. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.65. Coeptis Therapeutics Holdings' value of 63.60% is 334.1% above this industry median. Overall, Coeptis Therapeutics Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Coeptis Therapeutics Holdings' 3-Year EBITDA Growth Rate compare to ANIX and COYA?
Coeptis Therapeutics Holdings' 3-Year EBITDA Growth Rate of 63.60% can be compared against companies in the Biotechnology industry. The industry median 3-Year EBITDA Growth Rate is 14.65. Coeptis Therapeutics Holdings' value of 63.60% is 334.1% above this benchmark. While the company's 10-year median is 27.00 vs. the industry median of 14.65, Coeptis Therapeutics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.65, based on 1,124 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coeptis Therapeutics Holdings's current 3-Year EBITDA Growth Rate of 63.60% is 334.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Coeptis Therapeutics Holdings and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coeptis Therapeutics Holdings's current 3-Year EBITDA Growth Rate is 63.60%, which is 136% above median its own 10-year median of 27.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coeptis Therapeutics Holdings stock overvalued right now?
Coeptis Therapeutics Holdings (COEP) has a current 3-Year EBITDA Growth Rate of 63.60%. The current 3-Year EBITDA Growth Rate is 63.60%, which is 136% above median its 10-year median of 27.00 and 334.1% above the Biotechnology industry median of 14.65. Coeptis Therapeutics Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Coeptis Therapeutics Holdings (COEP), the current 3-Year EBITDA Growth Rate is 63.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Coeptis Therapeutics Holdings Business Description

Address 105 Bradford Road, Suite 420, Wexford, PA, USA, 15090
Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.
12GF Score

Get the complete analysis for COEP

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.40
Price